What is the appropriate workup for a patient with cardiomegaly?

Workup for Cardiomegaly

Begin with a 12-lead ECG, transthoracic echocardiography (TTE), and chest X-ray as the foundational triad for evaluating cardiomegaly, followed by targeted laboratory testing and advanced imaging based on initial findings. 1, 2

Initial Diagnostic Evaluation

Core Imaging Studies

• 12-lead ECG is mandatory in all patients with suspected cardiomegaly to identify left ventricular hypertrophy (LVH), conduction abnormalities, arrhythmias (particularly atrial fibrillation), and patterns suggesting specific etiologies like Wolff-Parkinson-White syndrome 1, 2, 3

• Transthoracic echocardiography (TTE) is the primary imaging modality for confirming cardiomegaly and determining its cause, assessing chamber dimensions, wall thickness (≥15 mm in adults suggests hypertrophic cardiomyopathy), systolic and diastolic function, valve abnormalities, and pericardial effusion 1, 2, 4

• Chest X-ray (posteroanterior and lateral views) provides initial assessment of cardiac silhouette size (cardiothoracic ratio >0.5 suggests cardiomegaly), pulmonary vascularity, pleural effusions, and can identify pulmonary causes of dyspnea 5, 6

Important caveat: Cardiomegaly on chest X-ray has only 56% positive predictive value for true cardiac enlargement, with 40% sensitivity and 91% specificity when compared to echocardiography 7. Therefore, all patients with cardiomegaly on chest X-ray require echocardiographic confirmation 7.

Laboratory Testing

• Complete blood count to assess for anemia (which can cause high-output cardiomegaly) 6

• Serum electrolytes, creatinine, and estimated GFR to evaluate renal function and electrolyte abnormalities 6

• Liver function tests to assess for hepatic congestion in heart failure 6

• Thyroid function tests to exclude thyroid-related cardiomyopathy 6

• BNP or NT-proBNP levels: BNP >100 pg/mL or NT-proBNP >400 pg/mL increases likelihood of heart failure; BNP >400 pg/mL or NT-proBNP >2000 pg/mL makes chronic heart failure likely 6, 8

• Glucose and hemoglobin A1c to identify diabetes (associated with cardiomegaly) 8, 9

Arrhythmia Screening

• 24- to 48-hour ambulatory (Holter) monitoring is recommended in the initial evaluation to detect ventricular tachycardia (for sudden cardiac death risk stratification) and paroxysmal atrial fibrillation 1, 2, 3

• Extended ambulatory monitoring (>24 hours) or event recording should be performed if patients develop palpitations or lightheadedness 1, 2, 3

• Repeat Holter monitoring every 1-2 years is reasonable for ongoing surveillance, particularly in patients with risk factors for atrial fibrillation (left atrial dilation, advanced age, NYHA class III-IV heart failure) 3

Determining the Underlying Etiology

Systematic Approach to Diagnosis

The detection of increased cardiac size should prompt a systematic search for the underlying cause through evaluation of: 10

• Family history and pedigree analysis for inherited cardiomyopathies 10

• Non-cardiac symptoms and signs suggesting systemic diseases (e.g., neuromuscular disorders, metabolic storage diseases, amyloidosis, sarcoidosis) 10, 4

• Medication history for drugs causing LVH (anabolic steroids, tacrolimus, hydroxychloroquine—though rarely causing wall thickness ≥15 mm) 10

• Endocrine evaluation for acromegaly, pheochromocytoma, or diabetes (infants of diabetic mothers) 10

Specialized Testing When Indicated

• Cardiac MRI (CMR) should be performed when echocardiography is non-diagnostic or to assess for myocardial fibrosis (late gadolinium enhancement), apical aneurysm, massive LVH, or infiltrative diseases like sarcoidosis or amyloidosis 3, 4

• Cardiac CT may be considered if echocardiography is non-diagnostic and CMR is unavailable or contraindicated, and can assess coronary anatomy 3

• Genetic testing is recommended in patients with hypertrophic cardiomyopathy (wall thickness ≥15 mm unexplained by loading conditions) or atypical presentations to facilitate cascade screening of first-degree relatives 1, 2

• Specialized laboratory tests for suspected infiltrative diseases:

  • Serum and urine protein electrophoresis for amyloidosis 10
  • Enzyme assays for storage diseases (Fabry disease, Pompe disease, Danon disease) 10
  • Angiotensin-converting enzyme (ACE) levels for sarcoidosis 4

Diagnostic Challenges Requiring Special Attention

• Physiological hypertrophy in athletes versus pathological hypertrophy (requires careful differentiation) 10

• Coexistent hypertension complicating the diagnosis of primary cardiomyopathy 10

• Isolated basal septal hypertrophy in elderly patients (may be age-related rather than pathological) 10

• Late-stage disease with dilated, hypokinetic left ventricle and wall thinning (end-stage hypertrophic cardiomyopathy) 10

• Epicardial adipose tissue can cause apparent cardiomegaly on chest X-ray and is associated with coronary risk factors, coronary calcification, and obstructive coronary disease 9

Family Screening Protocol

When cardiomegaly is confirmed as hypertrophic cardiomyopathy or familial cardiomyopathy:

• Screen all first-degree relatives with clinical evaluation, 12-lead ECG, and TTE 1, 2

• Children and adolescents: Screening every 12-18 months starting by age 12 years (or earlier if growth spurt, puberty, competitive sports participation, or family history of sudden cardiac death) 1, 2

• Adults: Screening approximately every 5 years unless genotype-positive/phenotype-negative, which requires more frequent monitoring 1, 2